Rheumatoid Arthritis - Early Therapy With Humira® and Methotrexate May Affect Long-Term Disease

Rheumatoid arthritis (RA) patients whose joint damage was inhibited through a combination therapy of HUMIRA® (adalimumab)
and methotrexate (MTX) early in the course of their disease were less likely to experience further damage two years later,
according to a new Abbott study. The PREMIER study found that patients with early RA (less than three years of disease
duration) who were treated for six months with a combination of HUMIRA and methotrexate experienced significantly less
radiographic progression (joint damage) compared to patients who took MTX alone. The data were presented at the annual
congress of the European League Against Rheumatism (EULAR).


In addition, PREMIER results also indicate that approximately one in two patients achieved clinical remission (defined as
DAS28







Clinical Remission Achieved with Early Treatment


PREMIER data also show that nearly half (49 percent) of early RA patients receiving combination therapy achieved clinical
remission, as defined by DAS28